Myriad Genetics (MYGN) Projected to Post Quarterly Earnings on Thursday

Myriad Genetics (NASDAQ:MYGN) will likely be issuing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Myriad Genetics to post earnings of ($0.03) per share and revenue of $206.0260 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Myriad Genetics had a negative net margin of 48.24% and a negative return on equity of 8.51%. The business had revenue of $200.40 million for the quarter, compared to analysts’ expectations of $202.42 million. During the same period last year, the business earned ($0.03) earnings per share. The company’s revenue was up 2.3% on a year-over-year basis. On average, analysts expect Myriad Genetics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Myriad Genetics Trading Down 1.6%

NASDAQ:MYGN opened at $5.61 on Friday. The firm has a market capitalization of $529.86 million, a P/E ratio of -1.30 and a beta of 1.64. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.40 and a quick ratio of 2.19. Myriad Genetics has a one year low of $3.53 and a one year high of $8.59. The company’s 50-day simple moving average is $4.99 and its 200 day simple moving average is $4.99.

Insider Buying and Selling

In other Myriad Genetics news, Director Paul Bisaro bought 7,500 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were acquired at an average cost of $3.69 per share, for a total transaction of $27,675.00. Following the purchase, the director owned 97,441 shares in the company, valued at approximately $359,557.29. This trade represents a 8.34% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rashmi Kumar sold 15,000 shares of Myriad Genetics stock in a transaction on Monday, June 8th. The stock was sold at an average price of $4.46, for a total value of $66,900.00. Following the completion of the sale, the director directly owned 171,889 shares of the company’s stock, valued at approximately $766,624.94. The trade was a 8.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Myriad Genetics

Several institutional investors have recently modified their holdings of MYGN. Invesco Ltd. boosted its position in shares of Myriad Genetics by 2.4% during the fourth quarter. Invesco Ltd. now owns 507,180 shares of the company’s stock valued at $3,119,000 after buying an additional 12,026 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in Myriad Genetics by 62.7% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 26,886 shares of the company’s stock worth $165,000 after buying an additional 10,359 shares during the last quarter. Vestal Point Capital LP lifted its stake in Myriad Genetics by 103.8% during the 4th quarter. Vestal Point Capital LP now owns 1,223,000 shares of the company’s stock valued at $7,521,000 after acquiring an additional 623,000 shares during the period. Tudor Investment Corp ET AL bought a new position in Myriad Genetics during the 4th quarter valued at about $276,000. Finally, Oxford Asset Management LLP purchased a new stake in shares of Myriad Genetics during the 4th quarter valued at about $143,000. 99.02% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on MYGN shares. Wells Fargo & Company lowered their target price on shares of Myriad Genetics from $6.00 to $5.50 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. TD Cowen reduced their price objective on Myriad Genetics from $7.00 to $6.00 and set a “hold” rating for the company in a research report on Wednesday, May 6th. Finally, Weiss Ratings upgraded Myriad Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.50.

Myriad Genetics Company Profile

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.